PubMed · 1998 · 18 citations · 6 references
MedicineNeuroscienceNuclear MedicineClinical NeuroscienceNeuropharmacologyNeuropsychiatryBrain ImagingGabaergic NeurochemistryGabaergic PharmacologyGabaergic SignalingBenzodiazepine Binding SitesBrain Perfusion ScintigraphyCerebral Blood Flow AlterationsIodine-123 ImagingIodine-123 ScintigraphyLigand-receptor AffinityReceptor Affinity MeasurementReceptor Affinity Regulation
UNLABELLED: Benzodiazepine receptor binding was assessed in four Japanese men with Machado-Joseph disease. METHODS: The distribution of benzodiazepine receptors was measured by radionuclide imaging (SPECT) after intravenous administration of 123I-iomazenil (Ro 16-0154). RESULTS: SPECT demonstrated decreased binding throughout the cerebral cortex and cerebellum in all patients. Binding potential (receptor concentration x affinity) was diffusely decreased in cerebral cortex, thalamus, striatum and cerebellum compared with control subjects, suggesting that GABAergic function may be decreased globally in these patients. Cerebral blood flow was largely normal, and no cerebral cortical atrophy was evident on MRI. CONCLUSION: Iodine-123-iomazenil SPECT may become a potent method for detecting impairment of the cerebral cortex even before brain perfusion SPECT or MRI can reveal early abnormalities.
6
Noninvasive quantification of iodine-123-iomazenil SPECT.
Yuki ONISHI, Yoshiharu Yonekura, Sadahiko Nishizawa et al. · PubMed · 1996 · 28 citations
Joseph disease: an autosomal dominant motor system degeneration.
Rosenberg Rn · PubMed · 1984 · 27 citations